Gold prices slip after rallying on Powell rate cut talk
Kavita Patel, a director at Arcellx , Inc. (NASDAQ:ACLX), a biotechnology company currently valued at $3.5 billion with a strong financial health score according to InvestingPro, recently executed a significant stock transaction. On February 25, 2025, Patel sold 1,500 shares of the company’s common stock at $63.16 per share, totaling approximately $94,740. This sale was conducted under a Rule 10b5-1 trading plan, which Patel entered into on March 28, 2024. The transaction comes as analysts maintain a strong buy consensus with price targets ranging from $104 to $134.
In addition to the sale, Patel also exercised stock options to acquire 1,500 shares at a price of $6.66 per share, amounting to a total value of $9,990. Following these transactions, Patel does not own any remaining shares from this particular batch of transactions.
The stock options exercised were part of Arcellx’s 2017 Equity Incentive Plan. According to this plan, 25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date, with the remainder vesting monthly over the subsequent years.
In other recent news, Arcellx Inc. has been the focus of several analyst updates following the release of promising data for its anito-cel treatment targeting multiple myeloma. Stifel reiterated its Buy rating with a $122 price target, highlighting the potential of anito-cel in the multiple myeloma market and noting its favorable safety profile compared to cilta-cel. Analysts at TD Cowen also maintained a Buy rating, emphasizing anito-cel’s comparable efficacy to Carvykti but with a better safety profile, particularly in terms of reduced neurotoxicity and cytokine release syndrome. BofA Securities increased its price target for Arcellx from $100 to $112, citing the positive interim pivotal iMMagine-1 data and the treatment’s competitive advantages over Carvykti, including higher manufacturing success rates.
The recent data from the iMMagine-1 trial showcased a 97% overall response rate and a 62% complete response rate, with minimal residual disease negativity in 93% of patients. Analysts are optimistic that these results, alongside anito-cel’s manufacturing capabilities, position Arcellx as a strong contender in the market. The firm’s collaboration with Gilead Sciences (NASDAQ:GILD) is seen as a strategic move to capture a majority market share. Despite some investor skepticism about long-term safety, particularly regarding Parkinsonism, analysts believe that additional follow-up data could further bolster confidence in anito-cel’s safety profile. These developments are being closely monitored by stakeholders, with the potential for Arcellx to secure a significant portion of the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.